HP
Therapeutic Areas
Alvotech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AVT02 (adalimumab biosimilar) | Immunology | Approved |
| AVT04 (ustekinumab biosimilar) | Immunology | Approved |
| AVT03 (denosumab biosimilar) | Bone Disease | Approved |
| AVT05 (golimumab biosimilar) | Immunology | Approved |
| AVT06 (aflibercept biosimilar) | Ophthalmology | Approved |
| AVT23 (omalizumab biosimilar) | Respiratory | Early Phase |
| AVT16 (vedolizumab biosimilar) | Immunology | Early Phase |
| AVT33 (pembrolizumab biosimilar) | Oncology | Early Phase |
Leadership Team at Alvotech
RW
Róbert Wessman
Founder, Chairman and Chief Executive Officer
TZ
Tanya Zharov
General Counsel
LJ
Linda Jónsdóttir
Chief Financial Officer
JE
Joseph E. McClellan
Chief Operating Officer
AM
Anthony M. Maffia III
Chief Quality and Regulatory Officer
DB
Dr. Balaji Prasad, MD
Chief Strategy Officer
KG
Kathryn Gunnarsson
Senior Vice President, Global Talent & People Experience
RD
Richard Davies
Director and Deputy Chairman
AH
Arni Hardarson
Director
LG
Lisa Graver
Director